These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25600085)

  • 1. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects.
    Couroux P; Patel D; Armstrong K; Larché M; Hafner RP
    Clin Exp Allergy; 2015 May; 45(5):974-981. PubMed ID: 25600085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.
    Patel D; Couroux P; Hickey P; Salapatek AM; Laidler P; Larché M; Hafner RP
    J Allergy Clin Immunol; 2013 Jan; 131(1):103-9.e1-7. PubMed ID: 22981787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis.
    Worm M; Patel D; Creticos PS
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1347-57. PubMed ID: 23964728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
    Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
    J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs).
    Klimek L; Pfaar O; Worm M
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1123-35. PubMed ID: 27191353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.
    Alexander C; Tarzi M; Larché M; Kay AB
    Allergy; 2005 Oct; 60(10):1269-74. PubMed ID: 16134993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy.
    Rudulier CD; Tonti E; James E; Kwok WW; Larché M
    Allergy; 2019 Nov; 74(11):2157-2166. PubMed ID: 31077596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhinoconjunctivitis severity induced by cat exposure influences early and late asthmatic responses: Evidence from an environmental exposure chamber.
    Piotin A; Godet J; Domis N; de Blay F
    Clin Exp Allergy; 2024 Aug; 54(8):596-606. PubMed ID: 38660824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The major cat allergen, Fel d 1, in diagnosis and therapy.
    Grönlund H; Saarne T; Gafvelin G; van Hage M
    Int Arch Allergy Immunol; 2010; 151(4):265-74. PubMed ID: 19844127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
    Shamji MH; Singh I; Layhadi JA; Ito C; Karamani A; Kouser L; Sharif H; Tang J; Handijiev S; Parkin RV; Durham SR; Kostic A; Orengo JM; DeVeaux M; Kamal M; Stahl N; Yancopoulos GD; Wang CQ; Radin AR
    Am J Respir Crit Care Med; 2021 Jul; 204(1):23-33. PubMed ID: 33651675
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficiency of peptide immunotherapy for respiratory allergy.
    Incorvaia C; Montagni M; Ridolo E
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):831-7. PubMed ID: 26901667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of ALLERVAX CAT in cat allergic patients.
    Maguire P; Nicodemus C; Robinson D; Aaronson D; Umetsu DT
    Clin Immunol; 1999 Dec; 93(3):222-31. PubMed ID: 10600332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections.
    Senti G; Crameri R; Kuster D; Johansen P; Martinez-Gomez JM; Graf N; Steiner M; Hothorn LA; Grönlund H; Tivig C; Zaleska A; Soyer O; van Hage M; Akdis CA; Akdis M; Rose H; Kündig TM
    J Allergy Clin Immunol; 2012 May; 129(5):1290-6. PubMed ID: 22464647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of bystander tolerance and immune deviation after Fel d 1 peptide immunotherapy.
    Moldaver DM; Bharhani MS; Rudulier CD; Wattie J; Inman MD; Larché M
    J Allergy Clin Immunol; 2019 Mar; 143(3):1087-1099.e4. PubMed ID: 29906527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1.
    Haselden BM; Syrigou E; Jones M; Huston D; Ichikawa K; Chapman MD; Kay AB; Larché M
    J Allergy Clin Immunol; 2001 Sep; 108(3):349-56. PubMed ID: 11544452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.